Effects of Dapagliflozin on Progression of Alport Syndrome

Exclusion Criteria

• •Concurrence of other types of kidney disease;
• •type 1 or type 2 diabetes;
• •use of other types of sodium-glucose cotransporter 2 inhibitors within the month prior to enrollment, or prior allergy to such drugs;
• •ACEI combined with ARB, or direct renin inhibitors, aldosterone receptor antagonists;
• •Uncontrolled hypertension (blood pressure greater than 160/90 mmHg during screening);
• •Patients undergoing renal transplantation or maintenance dialysis treatment;
• •Coexist with other serious and/or unstable diseases, such as serious cardiovascular diseases, respiratory diseases, liver diseases or neuropsychiatric diseases;
• •Patients who are participating in clinical trials of other drugs;
• •Pregnant or lactating women, or patients who do not want to receive contraception.